Abbott Laboratories

As of March 31, 2026, Abbott Laboratories carries a market capitalization of 153.85B, placing it among publicly traded companies globally. Its enterprise value stands at 177.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Abbott Laboratories's next confirmed earnings release is scheduled for January 27, 2027.

As of March 31, 2026, Abbott Laboratories has 1.74B shares outstanding.

As of March 31, 2026, Abbott Laboratories trades at a trailing price-to-earnings ratio of 28.30. The price-to-sales ratio is 3.94, and the price-to-book ratio stands at 3.42.

As of March 31, 2026, Abbott Laboratories trades at an EV/EBITDA multiple of 18.88 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 26.64 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Abbott Laboratories trades at an EV/FCF ratio of 26.34, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 177.55B versus a market cap of 153.85B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Abbott Laboratories maintains a current ratio of 1.39, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 64.60, indicating elevated leverage, while an interest coverage ratio of 20.28 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Abbott Laboratories posted a return on equity (ROE) of 12.44, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.97 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.54, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.98, useful for judging operating efficiency across full business cycles. The company generates approximately 341,008.06 in revenue per employee across its workforce of 114,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.90 indicates how many times Abbott Laboratories sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Abbott Laboratories recorded 1.61B in income tax expense. That works out to an effective tax rate of 22.87, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.04B, leaving 5.43B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 6, 2026, Abbott Laboratories's stock has declined approximately 22.84% over the past 52 weeks. The 50-day moving average sits at 92.63, while the 200-day moving average is 89.06.

Over the twelve months ended March 31, 2026, Abbott Laboratories generated 39.05B in revenue and converted that into 5.43B in net income, yielding earnings per share of 3.11. EBITDA reached 9.40B, while operating income came in at 6.67B.

As of March 31, 2026, Abbott Laboratories holds 6.31B in cash and equivalents against 29.45B in total debt, resulting in a net debt position of 23.57B. Total book value stands at 45.04B, with working capital of 6.17B providing operational flexibility.

Abbott Laboratories produced 8.19B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -1.80B in capital expenditures, free cash flow totaled 6.38B - equivalent to 3.67 per share.

Over the twelve months ended March 31, 2026, Abbott Laboratories posted a gross margin of 56.26, reflecting its pricing power and cost economics. The operating margin of 17.07 and net profit margin of 13.91 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Abbott Laboratories paid dividends of 2.08 per share. The dividend payout ratio of 66.73 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.13, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -7.34, meaning Abbott Laboratories raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Abbott Laboratories's most recent stock split took place on June 1, 1998 with a 1:2 split ratio.

As of March 31, 2026, Abbott Laboratories has an Altman Z-Score of 4.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.